Literature DB >> 1321736

The hepatic interleukin-6 receptor. Down-regulation of the interleukin-6 binding subunit (gp80) by its ligand.

D Zohlnhöfer1, L Graeve, S Rose-John, H Schooltink, E Dittrich, P C Heinrich.   

Abstract

Interleukin-6 (IL6) exerts its action via a cell surface receptor composed of an 80 kDa IL6-binding protein (gp80) and a 130 kDa polypeptide involved in signal transduction (gp130). We studied the role of gp80 in binding, internalization and down-regulation of the hepatic IL6-receptor (IL6R) by its ligand in human hepatoma cells (HepG2). Comparison of transfected HepG2 cells overexpressing gp80 with parental cells indicate that gp80 is responsible for low affinity binding (Kd = 500 pM) of IL6. Furthermore, gp80 is rate-limiting in internalization and degradation of IL6. Internalization resulted in a rapid down-regulation (t1/2 approximately 15-30 min) of IL6-binding sites at the cell surface. More than 80% of the internalized [125I]rhIL6 was degraded. The reappearance of IL6-binding sites at the cell surface required greater than 8 h and was sensitive to cycloheximide, suggesting that gp80 is not recycled after internalization. The down-regulation of the hepatic IL6R by its ligand might play an important role as a protection against overstimulation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321736     DOI: 10.1016/0014-5793(92)81004-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  30 in total

1.  Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.

Authors:  Patrick M Glassman; Yang Chen; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-12       Impact factor: 2.745

Review 2.  Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.

Authors:  Christopher J Carbone; Serge Y Fuchs
Journal:  J Cell Biochem       Date:  2014-01       Impact factor: 4.429

3.  Internalization of the interleukin 6 signal transducer gp130 does not require activation of the Jak/STAT pathway.

Authors:  S Thiel; I Behrmann; E Dittrich; L Muys; J Tavernier; J Wijdenes; P C Heinrich; L Graeve
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

4.  Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane.

Authors:  Andreas Schroers; Oliver Hecht; Karl-Josef Kallen; Michael Pachta; Stefan Rose-John; Joachim Grötzinger
Journal:  Protein Sci       Date:  2005-03       Impact factor: 6.725

5.  Effect of the selective and non-selective cysteine protease inhibitors on the intracellular processing of interleukin 6 by HEPG2 cells.

Authors:  J V Peppard; A K Knap
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-09       Impact factor: 2.416

6.  The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.

Authors:  Paul Baran; Selina Hansen; Georg H Waetzig; Mohammad Akbarzadeh; Larissa Lamertz; Heinrich J Huber; M Reza Ahmadian; Jens M Moll; Jürgen Scheller
Journal:  J Biol Chem       Date:  2018-03-20       Impact factor: 5.157

Review 7.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

8.  Interferon-alpha down-regulates the interleukin-6 receptor in a human multiple myeloma cell line, U266.

Authors:  J C Anthes; Z Zhan; H Gilchrest; R W Egan; M I Siegel; M M Billah
Journal:  Biochem J       Date:  1995-07-01       Impact factor: 3.857

Review 9.  Proinflammatory stem cell signaling in cardiac ischemia.

Authors:  Jeremy L Herrmann; Troy A Markel; Aaron M Abarbanell; Brent R Weil; Meijing Wang; Yue Wang; Jiangning Tan; Daniel R Meldrum
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

10.  The 55-kD tumor necrosis factor receptor on human keratinocytes is regulated by tumor necrosis factor-alpha and by ultraviolet B radiation.

Authors:  U Trefzer; M Brockhaus; H Lötscher; F Parlow; A Budnik; M Grewe; H Christoph; A Kapp; E Schöpf; T A Luger
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.